Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

179 results about "Heart muscles" patented technology

System for cardiac procedures

A system for accessing a patient's cardiac anatomy which includes an endovascular aortic partitioning device that separates the coronary arteries and the heart from the rest of the patient's arterial system. The endovascular device for partitioning a patient's ascending aorta comprises a flexible shaft having a distal end, a proximal end, and a first inner lumen therebetween with an opening at the distal end. The shaft may have a preshaped distal portion with a curvature generally corresponding to the curvature of the patient's aortic arch. An expandable means, e.g. a balloon, is disposed near the distal end of the shaft proximal to the opening in the first inner lumen for occluding the ascending aorta so as to block substantially all blood flow therethrough for a plurality of cardiac cycles, while the patient is supported by cardiopulmonary bypass. The endovascular aortic partitioning device may be coupled to an arterial bypass cannula for delivering oxygenated blood to the patient's arterial system. The heart muscle or myocardium is paralyzed by the retrograde delivery of a cardioplegic fluid to the myocardium through patient's coronary sinus and coronary veins, or by antegrade delivery of cardioplegic fluid through a lumen in the endovascular aortic partitioning device to infuse cardioplegic fluid into the coronary arteries. The pulmonary trunk may be vented by withdrawing liquid from the trunk through an inner lumen of an elongated catheter. The cardiac accessing system is particularly suitable for removing the aortic valve and replacing the removed valve with a prosthetic valve.
Owner:EDWARDS LIFESCIENCES LLC

Progressive biventricular diastolic support device

A device is proposed to progressively reduce the hemodynamic cardiac symptoms of congestive heart failure as well as those induced by dilated cardiomyopathies. This device affords progressive diastolic ventricular control by offering a method for percutaneous access and adjustments of its gas filled bladders surrounding the heart. After opening the pericardium, the device is not attached to the heart muscle but may be anchored to the pericardial sac. The device actually extends primarily around the heart from below the atrio-ventricular canal to the cardiac apex. Between the device exterior, made of non-elastic material and the epicardium, two independent elastic bladders or chambers provide variable compressive diastolic support to the right and left ventricles, while allowing adequate blood flow to the anterior and posterior descending epicardial branches of the coronary arteries and veins. Progressive hemodynamic increases in diastolic pressures for the right and left ventricles can be individually and repeatedly monitored by pressure gauges and an inert gas separately injected or removed in the enclosed chest through self-sealing access ports. These ports are subcutaneously implanted in the left anterior axillary line and connected by thin tubes across the 4th or 5th intercostal spaces to the pericardial bladders or chambers described above.
Owner:ROBERTSON JR ABEL L

Preventing and/or treating cardiovascular disease and/or associated heart failure

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.
Owner:PHILERA NEW ZEALAND +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products